The U.S. market for new obesity drugs is much larger than Europe’s. Substantially lower obesity prevalence in Europe is an obvious reason. But there are many others.
U.S. Market For New Wave Of Obesity Drugs Is Much Bigger Than Europe’s For Many Reasons
